Accessibility settings

This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (764) Cancer Survivorship (380) Clinical Cancer Research (140) Pathology and Laboratory Medicine (40) Diabetes (302) Precision Medicine (199) Drug discovery and development (12)

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/76811, first published .
Doctor points to pancreas model, explaining to patient in background.

IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study

IL-6/GP130/JAK/STAT3 Pathway Activation in Pancreatic Ductal Adenocarcinoma and Its Association With Clinical Features: Protocol for a Retrospective Cross-Sectional Study

Authors of this article:

Claudia Mellenthin1, 2 Author Orcid Image ;   Fabien Schaller1, 2 Author Orcid Image ;   Lucie Vignot3 Author Orcid Image ;   Sarah Peisl4 Author Orcid Image ;   Rita Vesce5 Author Orcid Image ;   Irene Esposito5 Author Orcid Image ;   Carmen Gonelle-Gispert2 Author Orcid Image ;   Cornelia Schneider6, 7 Author Orcid Image ;   Michel Adamina2, 4 Author Orcid Image ;   Leo Hans Bühler1, 2 Author Orcid Image
Article Authors Cited by (1) Tweetations Metrics

Journals

  1. Popatia A, Sharanek A, Jahani-Asl A. Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation. Signal Transduction and Targeted Therapy 2026;11(1) View